United Therapeutics (UTHR) Non-Current Assets (2009 - 2026)
United Therapeutics (UTHR) posted Non-Current Assets of $3.8 billion for Q1 2026, down 8.03% sequentially from $4.2 billion in Q4 2025, and up 1.0% YoY from $3.8 billion in Q1 2025.
United Therapeutics (UTHR) Non-Current Assets (2009 - 2026) Analysis & Trends
United Therapeutics has reported Non-Current Assets for 18 years, with the latest figure at $3.8 billion in Q1 2026.
- Quarterly Non-Current Assets rose 1.0% year-over-year to $3.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.0 billion (up 149.34% YoY) and the FY2025 annual result came in at $4.2 billion, up 19.7% from the prior year.
- Non-Current Assets fell to $3.8 billion in Q1 2026 per UTHR's latest filing, from $4.2 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $4.2 billion in Q4 2025 and troughed at -$4.0 billion in Q3 2024.
- A 5-year average of $3.0 billion and a median of $3.5 billion in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets sank 212.15% in 2024, then jumped 196.48% in 2025.
- Over 5 years, Non-Current Assets stood at $2.7 billion in 2022, then surged by 35.73% to $3.6 billion in 2023, then slipped by 3.48% to $3.5 billion in 2024, then gained by 19.7% to $4.2 billion in 2025, then retreated by 8.03% to $3.8 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $3.8 billion, $4.2 billion, and $3.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 2.96 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.74 Bn |
| Mar 31, 2026 | 3.84 Bn |
| Dec 31, 2025 | 4.18 Bn |
| Sep 30, 2025 | 3.86 Bn |
| Jun 30, 2025 | 4.08 Bn |
| Mar 31, 2025 | 3.80 Bn |
| Dec 31, 2024 | 3.49 Bn |
| Sep 30, 2024 | -4.00 Bn |
| Jun 30, 2024 | 3.10 Bn |
| Mar 31, 2024 | 3.25 Bn |
| Dec 31, 2023 | 3.62 Bn |
| Sep 30, 2023 | 3.56 Bn |
| Jun 30, 2023 | 3.47 Bn |
| Mar 31, 2023 | 3.15 Bn |
| Dec 31, 2022 | 2.66 Bn |
| Sep 30, 2022 | 2.73 Bn |
| Jun 30, 2022 | 2.86 Bn |
| Mar 31, 2022 | 2.77 Bn |
| Dec 31, 2021 | 2.85 Bn |
| Sep 30, 2021 | 2.66 Bn |